calliditas.se (CALT) - צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים

The quarterly EPS growth trend demonstrates the business's scalability potential: following successful tests, drug production costs remain minimal relative to profits. Strategic alliances are accelerating the expansion of orphan drugs, although integration with Asahi Kasei and pricing controls in the US are creating pressure. The value of 48.70 represents the latest metric reading, helping to assess the fundamental strength of Calliditas Therapeutics (CALT).

Analyzing net income per share dynamics is critical for selecting assets with a high margin of safety. This indicator measures EPS growth rates following 10-Q filings, allowing for an assessment of Calliditas Therapeutics (CALT) expansion efficiency through partnerships with STADA and Everest Medicines, which is clearly reflected in the quarterly EPS growth figure.